Albuminuria acts as a marker of progressive chronic kidney disease and as an indicator for initiation of hypertension treatment via modulation of the renin-angiotensin-aldosterone system with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors. However, the true significance of albuminuria has yet to be fully defined. Is it merely a marker of underlying pathophysiology, or does it play a causal role in the progression of kidney disease? The answer remains under debate. In this issue of the JCI, Bedin et al. used next-generation sequencing data to identify patients with chronic proteinuria who had biallelic variants in the cubilin gene (CUBN). Through investigation of these pathogenic mutations in CUBN, the authors have further illuminated the clinical implications of albuminuria.
CITATION STYLE
Beenken, A., Barasch, J. M., & Gharavi, A. G. (2020, January 2). Not all proteinuria is created equal. Journal of Clinical Investigation. American Society for Clinical Investigation. https://doi.org/10.1172/JCI133250
Mendeley helps you to discover research relevant for your work.